Search This Blog

Thursday, February 26, 2026

Aclaris misses EPS and revenue estimates

 

Aclaris Therapeutics reports Q4 2025 results with non-GAAP EPS -$0.16 and revenue $1.3M, misses EPS and revenue estimates

  • Company's 2025 results highlighted development milestones for ATI-052 and bosakitug programs
  • Ended 2025 with $151.4M in cash, expected to fund operations into H2 2028
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)